AliveCor announced today that it received FDA clearance for the next generation of its AI technology for the Kardia 12L ECG ...
The newly cleared features include three rhythm modifiers and two axis-related morphology determinations: RAD and LAD.
AliveCor, the global leader in AI-powered cardiology, today announced it has received U.S. Food and Drug Administration (FDA) ...
While AliveCore faced two wins, the dispute did not end there. In March 2025, Apple triumphed in a major patent dispute with ...
HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
An investigation has found a "concerning level of variation" in how 12-lead electrocardiogram (ECG) skills are taught in UK undergraduate paramedic programmes. A report by the Health Services Safety ...